Srini Vas Sadda

2 weeks ago | healio.com | Srini Vas Sadda |Alex Young |Anthony DeFino

SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, SriniVas R. Sadda, MD, FARVO, discusses a long-term study evaluating MCO-010 for the treatment of retinitis pigmentosa. Sadda said patients with retinitis pigmentosa experienced sustained improvements in visual acuity through 126 weeks after treatment with MCO-010 (Nanoscope Therapeutics). Additionally, the safety profile of the gene therapy was favorable, he said.